Allogeneic Hematopoietic Cell Transplantation in Patients with Primary Immunodeficiencies in Korea: Eleven-Year Experience in a Single Center
- Authors
- Yi, Eun Sang; Choi, Young Bae; Lee, Na Hee; Lee, Ji Won; Sung, Ki Woong; Koo, Hong Hoe; Kang, Eun-Sook; Kim, Yae-Jean; Yoo, Keon Hee
- Issue Date
- Oct-2018
- Publisher
- Kluwer Academic/Plenum Publishers
- Keywords
- Hematopoietic cell transplantation; bone marrow transplantation; primary immunodeficiency; child
- Citation
- Journal of Clinical Immunology, v.38, no.7, pp 757 - 766
- Pages
- 10
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- Journal of Clinical Immunology
- Volume
- 38
- Number
- 7
- Start Page
- 757
- End Page
- 766
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/3069
- DOI
- 10.1007/s10875-018-0542-7
- ISSN
- 0271-9142
1573-2592
- Abstract
- Purpose
We aimed to report our single-center experience of allogeneic hematopoietic cell transplantation (HCT), which has been the only curative option for certain patients with lethal primary immunodeficiencies (PIDs).
Methods
We summarized the results of HCT performed for patients with PIDs for 11 consecutive years from 2006 to 2016 at Samsung Medical Center, Seoul, Korea. Twenty-six patients with PIDs received HCT. Most had chronic granulomatous disease (42.3%), Wiskott Aldrich syndrome (15.4%), or severe combined immunodeficiency (11.5%).
Results
Nine patients (34.6%) received HCT during the former half period and 17 patients (65.4%) during the latter half period. Donor types were categorized as: matched sibling donor (n = 5), unrelated donor (n = 17), and familial mismatched donor (FMMD) (n = 4). Unrelated HCT and FMMD transplantation were increasingly performed in the latter half period compared to the first (5 vs. 16, P = 0.034). Five patients experienced initial engraftment failure, but all of them were eventually engrafted after additional HCTs. The 3-year probability of overall survival was 72.0%. Seven patients (26.9%) died, and the causes of death were bacterial sepsis (n = 4), pneumonia (n = 1), chronic graft-versus-host disease (GVHD) (n = 1), and diffuse alveolar hemorrhage (n = 1). Two patients with bacterial sepsis and a patient with pneumonia also had chronic GVHD. Unrelated HCT and use of methotrexate were associated with poor outcome. Complete chimerism was attained in 85.0% at 1 year after HCT.
Conclusion
PID candidates have been increasingly identified for allogeneic HCT in Korea, and the majority of them could be cured by HCT. Establishment of a systematic registry of PID patients for HCT is needed.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Pediatrics > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.